COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #209 of 237
12/11 Late treatment study
Bielza et al., Journal of the American Medical Directors Association, doi:10.1016/j.jamda.2020.12.003 (Peer Reviewed)
Clinical characteristics, frailty and mortality of residents with COVID-19 in nursing homes of a region of Madrid
Source   PDF   Share   Tweet
Retrospective 630 elderly patients in Spain showing lower mortality with HCQ treatment, unadjusted relative risk RR 0.78, p = 0.09. HCQ was used more often with patients that were hospitalized (24% versus 3% use in the nursing homes). Median age 87.

Bielza et al., 12/11/2020, retrospective, Spain, Europe, peer-reviewed, median age 87.0, 24 authors.
risk of death, 21.5% lower, RR 0.78, p = 0.09, treatment 33 of 91 (36.3%), control 249 of 539 (46.2%).
Details of all 237 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit